首页> 中文期刊> 《临床研究通讯》 >Meta-analysis of the efficacy and safety of sodium fusidate ointment and mupirocin ointment in the treatment of bacteria-infected skin disease

Meta-analysis of the efficacy and safety of sodium fusidate ointment and mupirocin ointment in the treatment of bacteria-infected skin disease

         

摘要

Objective:To evaluate the efficacy and safety of sodium fusidate ointment and mupirocin ointment in the treatment of bacteria-infected skin disease.Methods:The search terms“sodium fusidate ointment”,“mupirocin ointment”,“bacterial infection”,etc.were searched in the database of PubMed,EMbase,Cochrane,Web of Science,Wanfang,VIP,and CNKI.The search time was from inception to November 2019.Randomized controlled trials of sodium fusidate ointment and mupirocin ointment for the treatment of bacteria-infected skin disease were collected.Two studies independently performed literature screening,data extraction,and literature quality evaluation.Meta analysis was performed using RevMan 5.3 software.Results:A total of 14 literature were included,involving 1,825 patients,916 in the experimental group,and 909 in the control group.Meta analysis results showed that the total clinical effective rate of the experimental group(RR=1.12,95%CI(1.06,1.19),P<0.0001),degree of improvement in pruritus score(MD=−1.21,95%CI(−1.78,−0.64),P<0.0001),degree of improvement of eczema area and severity index score(MD=−2.47,95%CI(−3.92,−1.02),P=0.0008),and sensitivity rate of drug sensitivity test(RR=1.35,95%CI(1.24,1.46),P<0.00001)were better than those of control group.The incidence of adverse reactions(RR=0.18,95%CI(0.09,0.39),P<0.00001)was significantly smaller than that of control group.But the bacterial clearance rate(RR=1.22,95%CI(0.98,1.52),P=0.08)compared with the control group,the difference was not statistically significant.Conclusion:Sodium fusidate ointment is better than mupirocin ointment in the treatment of bacteria-infected skin disease,and it helps to improve the severity of disease and itching,and has good safety,which is worthy of clinical promotion.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号